The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Use of KRAS mutation status to predict clinical outcomes in patients with metastatic colorectal cancer (mCRC) treated with the VEGF signaling inhibitor cediranib.
J. M. Jürgensmeier
Employment or Leadership Position - AstraZeneca
Stock Ownership - AstraZeneca
P. M. Hoff
Consultant or Advisory Role - AstraZeneca
L. Pike
Employment or Leadership Position - AstraZeneca
Stock Ownership - AstraZeneca
J. D. Robertson
Employment or Leadership Position - AstraZeneca
Stock Ownership - AstraZeneca
S. Morgan
Employment or Leadership Position - AstraZeneca
Stock Ownership - AstraZeneca
G. McWalter
Employment or Leadership Position - AstraZeneca
Stock Ownership - AstraZeneca
D. Wilson
Employment or Leadership Position - AstraZeneca
Stock Ownership - AstraZeneca
J. C. Smith
Employment or Leadership Position - AstraZeneca
Stock Ownership - AstraZeneca